Time for arginine methylation: PRMT5 inhibition to advance cholangiocarcinoma treatment.
作者信息
Désert Romain, Goyal Lipika, Baumert Thomas F
机构信息
University of Strasbourg, Inserm, Institute for Translational Medicine and Liver Disease (ITM), UMR_S1110, Strasbourg, France.
Division of Oncology, Department of Medicine, Stanford School of Medicine, Palo Alto, California, USA.
出版信息
Gut. 2025 May 7;74(6):878-880. doi: 10.1136/gutjnl-2024-333632.
Abstract
摘要
相似文献
1
Time for arginine methylation: PRMT5 inhibition to advance cholangiocarcinoma treatment.精氨酸甲基化时机：抑制PRMT5以推进胆管癌治疗
Gut. 2025 May 7;74(6):878-880. doi: 10.1136/gutjnl-2024-333632.
2
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.鉴定PRMT5作为胆管癌的治疗靶点。
Gut. 2024 Dec 10;74(1):116-127. doi: 10.1136/gutjnl-2024-332998.
3
Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.靶向蛋白质精氨酸甲基转移酶5通过降低真核翻译起始因子4E（eIF4E）和纤维母细胞生长因子受体3（FGFR3）的精氨酸甲基化来抑制结直肠癌的生长。
Oncotarget. 2015 Sep 8;6(26):22799-811. doi: 10.18632/oncotarget.4332.
4
PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by polycomb complex PRC2.PRMT5 介导的组蛋白精氨酸甲基化拮抗多梳复合物 PRC2 的转录抑制。
Nucleic Acids Res. 2020 Apr 6;48(6):2956-2968. doi: 10.1093/nar/gkaa065.
5
Proteomics profiling of arginine methylation defines PRMT5 substrate specificity.精氨酸甲基化蛋白质组学分析定义了 PRMT5 底物特异性。
Sci Signal. 2019 Apr 2;12(575):eaat8388. doi: 10.1126/scisignal.aat8388.
6
PRMT5 activates AKT via methylation to promote tumor metastasis.PRMT5 通过甲基化激活 AKT 促进肿瘤转移。
Nat Commun. 2022 Jul 8;13(1):3955. doi: 10.1038/s41467-022-31645-1.
7
Inhibition of PRMT5/MEP50 Arginine Methyltransferase Activity Causes Cancer Vulnerability in NDRG2 Adult T-Cell Leukemia/Lymphoma.抑制PRMT5/MEP50精氨酸甲基转移酶活性会导致NDRG2成人T细胞白血病/淋巴瘤出现癌症易感性。
Int J Mol Sci. 2024 Feb 29;25(5):2842. doi: 10.3390/ijms25052842.
8
KSHV encoded ORF59 modulates histone arginine methylation of the viral genome to promote viral reactivation.卡波西肉瘤相关疱疹病毒编码的ORF59调节病毒基因组的组蛋白精氨酸甲基化以促进病毒再激活。
PLoS Pathog. 2017 Jul 5;13(7):e1006482. doi: 10.1371/journal.ppat.1006482. eCollection 2017 Jul.
9
Substrate adaptors are flexible tethering modules that enhance substrate methylation by the arginine methyltransferase PRMT5.底物衔接蛋白是一种灵活的拴系模块，可增强精氨酸甲基转移酶PRMT5介导的底物甲基化。
J Biol Chem. 2025 Feb;301(2):108165. doi: 10.1016/j.jbc.2025.108165. Epub 2025 Jan 8.
10
NF90/NFAR (nuclear factors associated with dsRNA) - a new methylation substrate of the PRMT5-WD45-RioK1 complex.NF90/NFAR（与双链 RNA 相关的核因子）- PRMT5-WD45-RioK1 复合物的新甲基化底物。
Biol Chem. 2022 Aug 31;403(10):907-915. doi: 10.1515/hsz-2022-0136. Print 2022 Sep 27.
引用本文的文献
1
Drug-Resistant Cholangiocarcinoma Cell Lines for Therapeutic Evaluation of Novel Drugs.用于新药治疗评估的耐药胆管癌细胞系
Molecules. 2025 Jul 21;30(14):3053. doi: 10.3390/molecules30143053.
本文引用的文献
1
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration.AMG 193（一种MTA协同PRMT5抑制剂）在MTAP缺失实体瘤患者中的首次人体研究：I期剂量探索结果
Ann Oncol. 2024 Dec;35(12):1138-1147. doi: 10.1016/j.annonc.2024.08.2339. Epub 2024 Sep 16.
2
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.鉴定PRMT5作为胆管癌的治疗靶点。
Gut. 2024 Dec 10;74(1):116-127. doi: 10.1136/gutjnl-2024-332998.
3
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers.甲基硫代腺苷磷酸化酶基因在晚期胃肠道癌症中的缺失。
Oncologist. 2024 Jun 3;29(6):493-503. doi: 10.1093/oncolo/oyae011.
4
The potential and challenges of targeting -negative cancers beyond synthetic lethality.超越合成致死性靶向阴性癌症的潜力与挑战。
Front Oncol. 2023 Sep 19;13:1264785. doi: 10.3389/fonc.2023.1264785. eCollection 2023.
5
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.MRTX1719 是一种 MTA-合作的 PRMT5 抑制剂，在临床前模型和 MTAP 缺失型癌症患者中表现出合成致死性。
Cancer Discov. 2023 Nov 1;13(11):2412-2431. doi: 10.1158/2159-8290.CD-23-0669.
6
Cholangiocarcinoma - novel biological insights and therapeutic strategies.胆管癌——新的生物学见解和治疗策略。
Nat Rev Clin Oncol. 2023 Jul;20(7):470-486. doi: 10.1038/s41571-023-00770-1. Epub 2023 May 15.
7
Clinical advances in epigenetic therapies for lymphoma.淋巴瘤表观遗传学治疗的临床进展。
Clin Epigenetics. 2023 Mar 4;15(1):39. doi: 10.1186/s13148-023-01452-6.
8
Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review.肿瘤学临床试验中的蛋白质精氨酸甲基转移酶5（PRMT5）抑制剂：综述
J Immunother Precis Oncol. 2022 Jun 22;5(3):58-67. doi: 10.36401/JIPO-22-1. eCollection 2022 Aug.
9
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.基于新型微环境的肝内胆管癌分类及其治疗意义。
Gut. 2023 Apr;72(4):736-748. doi: 10.1136/gutjnl-2021-326514. Epub 2022 May 18.
10
PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.PRMT5 缺失通过重编程 T 细胞介导的反应和调节 PD-L1 表达来驱动宫颈癌中的抗肿瘤免疫。
Theranostics. 2021 Aug 28;11(18):9162-9176. doi: 10.7150/thno.59605. eCollection 2021.
Zotero 插件